Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context. - Wikidata - awgldk - TriplyDB

Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.

Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.

http://www.wikidata.org/entity/Q49549481

about

Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.

http://www.wikidata.org/entity/Q49549481

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Fighting residual cardiovascul ...... r disease: COMPASS in context.

@en

Fighting residual cardiovascul ...... r disease: COMPASS in context.

@nl

type

label

Fighting residual cardiovascul ...... r disease: COMPASS in context.

@en

Fighting residual cardiovascul ...... r disease: COMPASS in context.

@nl

prefLabel

Fighting residual cardiovascul ...... r disease: COMPASS in context.

@en

Fighting residual cardiovascul ...... r disease: COMPASS in context.

@nl

P1433

Q49549481-7C079178-1FFC-4035-AAEC-A7D308DB274E

P1476

Q49549481-01EAA372-4D2B-416C-B9C4-CF384CB9AE5C

P2093

Q49549481-C513E77E-37E7-4F7C-BC13-9836F5123508

P2860

Q49549481-183C622E-3BA2-4DA1-B7BD-34B966D8C0FD

Q49549481-1DB99C3F-BDD8-4656-8A03-86A3887B5F15

Q49549481-2E5EACF1-F7B4-4541-80FB-1DA3DA5908DA

Q49549481-30B86F4E-DEE0-4312-B16C-5E9CC0F815A8

Q49549481-3E82869D-FFD6-4336-ABBD-BFCDBCA89542

Q49549481-A71AF0BD-BD85-4D4A-86E8-2563FDB2027B

Q49549481-C434FFB7-7F30-4034-BC54-697F56522BD1

Q49549481-D09F6B08-6BDE-48EB-8E75-AE3A2C7AC5D3

Q49549481-D7EBDE37-5A58-4307-A8C1-2BB08887D2C3

Q49549481-E199A183-8CD8-4ACC-93C5-A5586F3EC472

P304

Q49549481-03064F51-E4C3-4BA9-8A39-55EA0C04E2E6

P31

Q49549481-75C97D2C-F7D1-4D96-A01B-41D31A53F0F3

P356

Q49549481-999390AC-2C22-4C0E-B5F8-0877BF956BC8

P433

Q49549481-3CC061C8-7E76-49D8-A972-1020902F1ECB

P478

Q49549481-1A909B79-1E98-487B-B34A-66B7EADAF7C3

P577

Q49549481-AD5D550A-D556-43CD-97DC-92CB2F53FB15

P698

Q49549481-E90ECA45-EF97-4C42-A294-42B85452A314

P921

Q49549481-C78614EB-263D-459A-B6CB-6C920C2832BF

P356

P1433

Cardiovascular Research

P1476

Fighting residual cardiovascul ...... r disease: COMPASS in context.

@en

P2093

Carlo Patrono

http://www.w3.org/2001/XMLSchema#string

P2860

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

Vorapaxar in the secondary prevention of atherothrombotic events.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.

Long-term use of ticagrelor in patients with prior myocardial infarction.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.

Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.

P304

e61-e63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CVR/CVX209

http://www.w3.org/2001/XMLSchema#string

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29186439

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis